• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

病例报告：一名患有难治性系统性肥大细胞增多症合并AML1::ETO+急性髓系白血病的儿科患者对吉妥珠单抗-奥佐米星迅速产生反应。

Case Report: Rapid response to gemtuzumab-ozogamicin in a pediatric patient with refractory systemic mastocytosis with AML1::ETO+ acute myeloid leukemia.

作者信息

Xue Song, Chen Man, Sun Hui-Peng, Wang Tong, Zhang Li-Na, Cao Xing-Yu

机构信息

Department of Bone Marrow Transplant, Beijing Lu Daopei Hospital, Beijing, China.

Division of Pathology & Laboratory Medicine, Beijing Lu Daopei Hospital, Beijing, China.

出版信息

Front Immunol. 2025 Apr 9;16:1566805. doi: 10.3389/fimmu.2025.1566805. eCollection 2025.

DOI:10.3389/fimmu.2025.1566805
PMID:40270973
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12014624/
Abstract

This article describes a 6-year-old patient diagnosed with "systemic mastocytosis with AML1::ETO+ AML", he experience refractory disease during the course of treatment and salvage treatment was ineffective. The patient was administered gemtuzumab-ozogamicin therapy, resulting in rapid remission.

摘要

本文描述了一名6岁患者，被诊断为“伴有AML1::ETO+急性髓系白血病的系统性肥大细胞增多症”，他在治疗过程中出现难治性疾病，挽救治疗无效。该患者接受了吉妥珠单抗-奥唑米星治疗，迅速获得缓解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff25/12014624/fe8ae740f8b6/fimmu-16-1566805-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff25/12014624/4d5b3a695415/fimmu-16-1566805-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff25/12014624/6c54a4fb99db/fimmu-16-1566805-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff25/12014624/fe8ae740f8b6/fimmu-16-1566805-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff25/12014624/4d5b3a695415/fimmu-16-1566805-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff25/12014624/6c54a4fb99db/fimmu-16-1566805-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff25/12014624/fe8ae740f8b6/fimmu-16-1566805-g003.jpg

相似文献

1
Case Report: Rapid response to gemtuzumab-ozogamicin in a pediatric patient with refractory systemic mastocytosis with AML1::ETO+ acute myeloid leukemia.病例报告：一名患有难治性系统性肥大细胞增多症合并AML1::ETO+急性髓系白血病的儿科患者对吉妥珠单抗-奥佐米星迅速产生反应。
Front Immunol. 2025 Apr 9;16:1566805. doi: 10.3389/fimmu.2025.1566805. eCollection 2025.
2
Combined use of interferon alpha-1b, interleukin-2, and thalidomide to reverse the AML1-ETO fusion gene in acute myeloid leukemia.联合使用干扰素 alpha-1b、白细胞介素-2 和沙利度胺逆转急性髓系白血病中的 AML1-ETO 融合基因。
Ann Hematol. 2021 Oct;100(10):2593-2601. doi: 10.1007/s00277-021-04621-w. Epub 2021 Jul 27.
3
Co-expression of AML1-ETO and PML-RARa following treatment of de novo acute myeloid leukemia with AML1-ETO.用AML1-ETO治疗初发急性髓系白血病后AML1-ETO与PML-RARa的共表达
Leuk Lymphoma. 2019 May;60(5):1316-1319. doi: 10.1080/10428194.2018.1520991. Epub 2018 Oct 17.
4
Olaparib combined with low-dose chemotherapy for relapsed positive acute myeloid leukemia in elderly patient.奥拉帕利联合低剂量化疗用于老年复发阳性急性髓系白血病患者
Leuk Lymphoma. 2024 Aug;65(8):1181-1185. doi: 10.1080/10428194.2024.2337795. Epub 2024 Jul 23.
5
[Clinical features and prognosis of core binding factor acute myeloid leukemia children in South China: a multicenter study].[中国南方儿童核心结合因子急性髓系白血病的临床特征与预后：一项多中心研究]
Zhonghua Er Ke Za Zhi. 2023 Oct 2;61(10):881-888. doi: 10.3760/cma.j.cn112140-20230224-00126.
6
AML1-ETO inhibits acute myeloid leukemia immune escape by CD48.AML1-ETO 通过 CD48 抑制急性髓系白血病免疫逃逸。
Leuk Lymphoma. 2021 Apr;62(4):937-943. doi: 10.1080/10428194.2020.1849680. Epub 2020 Nov 21.
7
[Correlations Between - Fusion Gene and Clinical Features of Acute Myeloid Leukemia in Sichuan].[四川急性髓系白血病中 - 融合基因与临床特征的相关性]
Sichuan Da Xue Xue Bao Yi Xue Ban. 2016 Nov;47(6):931-935.
8
Histone deacetylase 3 preferentially binds and collaborates with the transcription factor RUNX1 to repress AML1-ETO-dependent transcription in t(8;21) AML.组蛋白去乙酰化酶 3 优先与转录因子 RUNX1 结合并协同作用，以抑制 t(8;21) AML 中 AML1-ETO 依赖性转录。
J Biol Chem. 2020 Mar 27;295(13):4212-4223. doi: 10.1074/jbc.RA119.010707. Epub 2020 Feb 18.
9
Homoharringtonine may help improve the outcomes of venetoclax and azacitidine in AML1-ETO positive acute myeloid leukemia.高三尖杉酯碱可能有助于改善 AML1-ETO 阳性急性髓系白血病患者中维奈托克和阿扎胞苷的疗效。
J Cancer Res Clin Oncol. 2024 Jul 6;150(7):336. doi: 10.1007/s00432-024-05861-9.
10
Relationships between AML1-ETO and MLL-AF9 fusion gene expressions and hematological parameters in acute myeloid leukemia.急性髓系白血病中 AML1-ETO 和 MLL-AF9 融合基因表达与血液学参数的关系。
Gulf J Oncolog. 2020 Sep;1(34):65-69.

本文引用的文献

1
KIT V560D-Mutated Systemic Mastocytosis Associated With High-Risk Myelodysplastic Syndrome: A Unique Case of Systemic Mastocytosis-Associated Hematologic Neoplasm.与高危骨髓增生异常综合征相关的KIT V560D突变型系统性肥大细胞增多症：系统性肥大细胞增多症相关血液肿瘤的一个独特病例。
Case Rep Hematol. 2024 Nov 30;2024:4360304. doi: 10.1155/crh/4360304. eCollection 2024.
2
Allogeneic haematopoietic cell transplantation for advanced systemic mastocytosis: Best practice recommendations on behalf of the EBMT Practice Harmonisation and Guidelines Committee.异基因造血细胞移植治疗晚期系统性肥大细胞增生症：EBMT 实践协调和指南委员会代表的最佳实践建议。
Leukemia. 2024 Apr;38(4):699-711. doi: 10.1038/s41375-024-02182-1. Epub 2024 Mar 12.
3
Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries.
异基因造血细胞移植治疗晚期系统性肥大细胞增生症：DRST 和 GREM 注册研究的回顾性分析。
Leukemia. 2024 Apr;38(4):810-821. doi: 10.1038/s41375-024-02186-x. Epub 2024 Mar 6.
4
Multicolor flow cytometric immunophenotyping is highly sensitive and specific in identifying aberrant mast cells in the diagnostic workup of systemic mastocytosis.多色流式细胞术免疫表型分析在系统性肥大细胞增多症的诊断中具有高度的敏感性和特异性，可以识别异常的肥大细胞。
Am J Clin Pathol. 2024 Jun 3;161(6):598-608. doi: 10.1093/ajcp/aqad187.
5
A multicenter retrospective comparison between systemic mastocytosis with t(8;21) AML and KIT mutant t(8;21) AML.伴有t(8;21)的系统性肥大细胞增多症AML与KIT突变型t(8;21) AML的多中心回顾性比较。
Blood Adv. 2024 Feb 27;8(4):889-894. doi: 10.1182/bloodadvances.2023012006.
6
Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management.成人系统性肥大细胞增多症：2023 年诊断、风险分层和治疗更新。
Am J Hematol. 2023 Jul;98(7):1097-1116. doi: 10.1002/ajh.26962. Epub 2023 May 22.
7
Rapid response to avapritinib of acute myeloid leukemia with t(8;21) and mutation relapse post allo-HSCT.伴t(8;21)的急性髓系白血病对阿伐替尼的快速反应及异基因造血干细胞移植后复发伴突变
Leuk Lymphoma. 2022 Sep;63(9):2247-2250. doi: 10.1080/10428194.2022.2064994. Epub 2022 Apr 19.
8
Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial.在晚期系统性肥大细胞增多症中阿伐普利替尼的安全性和疗效：EXPLORER 期试验。
Nat Med. 2021 Dec;27(12):2183-2191. doi: 10.1038/s41591-021-01538-9. Epub 2021 Dec 6.
9
Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial.晚期系统性肥大细胞增多症中 avapritinib 的疗效和安全性：2 期 PATHFINDER 试验的中期分析。
Nat Med. 2021 Dec;27(12):2192-2199. doi: 10.1038/s41591-021-01539-8. Epub 2021 Dec 6.
10
Avapritinib in the Treatment of Systemic Mastocytosis: an Update.阿伐普利替尼治疗系统性肥大细胞增生症：更新。
Curr Hematol Malig Rep. 2021 Oct;16(5):464-472. doi: 10.1007/s11899-021-00650-4. Epub 2021 Sep 27.